Higher Early Anti-TNF Levels May Be Crucial to Treatment Success

Posted by Michael Jannicelli | Oct 2, 2024 | Uncategorized | 0 |

In patients with Crohn’s disease a multicenter prospective study found that anti-TNF therapy failed to achieve remission at 3 years in about two-thirds of cases, and that high drug concentrations early in treatment are linked to greater probability of sustained remission. This suggests that getting biologic therapy right in induction is probably the most important part of treating Crohn’s disease with anti-TNFs.

[URL…

About The Author

Michael Jannicelli

Michael Jannicelli - "A PROVEN BUSINESS FIRESTARTER & BRANDING GENIUS" a true natural born Trendsetter. • Created over 100 products under 3 brands, sold in 30+ countries worldwide and influencing youth across the globe. • Featured in Forbes magazine +over 100 print publications, television talk shows, major motion pictures and national radio stations. • Co-founder and VP of Bliss beverage USA and President/co-founder of Socko International - fastest growing privately held beverage company in US (Forbes) with Hogan Energy & Raw Energy WWE. • Co-founder of Throwdown Industries (2003) - leading brand in multibillion dollar Impact/Action Sports Market (products designed for superior MN • Diagnosed with auto-immune diseases aged 13; using his experience to help others and promote a positive message while developing edgy products to benefit people with chronic illness.